Entrepreneur Kevin Gosnell announced the launch of ALS ONE – a partner organization of the ALS Association and ALS Finding a Cure that aims to bring world-leading experts in neurology and amyotrophic lateral sclerosis (ALS) care together to realize an ambitious goal: finding a new ALS treatment within four years.

CIRM has funded the ALS Disease Team led by scientists at UC San Diego, The Salk Institute, and Life Technologies Corporation, who aim to bring a human embryonic stem cell-based ALS therapy to clinical trials within four years. Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease, is…

A recent review summarized the effects of immune system dysregulation and neuroinflammation in the regulation of critical pathways associated with depression and other brain disorders, including amyotrophic lateral sclerosis (ALS). The researchers specifically focused on extracellular vesicles (EVs) as potential biomarkers and drug delivery vehicles. The review, “Neuroinflammation and Depression: Microglia Activation, Extracellular Microvesicles…

The ratio of N-acetyl aspartate (NAA) to glutamate is related to disease duration in patients with amyotrophic lateral sclerosis (ALS), a finding that supports the notion of glutamate toxicity as a contributing factor in ALS pathology. Earlier studies have indicated that the neurotransmitter glutamate is involved in ALS. People with sporadic ALS…

A panel of leading amyotrophic lateral sclerosis (ALS) researchers recently published a review study, supported by the ALS Association, detailing the state of disease biomarker development and calling for the formation of an ALS Biomarker Consortium to speed up research into more effective disease treatments. The review, titled “ALS biomarkers…

“Are and Yuki’s lives together were totally changed when Are was diagnosed with amyotrophic lateral sclerosis (ALS). Watch the touching moment when his children celebrate his birthday at the hospital.” Learn more about ALS: https://bit.ly/ALSNewsToday…

Motor neuron degeneration in amyotrophic lateral sclerosis (ALS) patients is caused by several factors, including inflammation and oxidative stress. Uncovering the multiple pathways leading to ALS may suggest new ways to intervene therapeutically. University of Pittsburgh researchers found the Receptor for Advanced Glycation End Products (RAGE) and its ligands, or…

A report in the journal JAMA Neurology revealed positive findings from the first Phase 1/2 clinical trial and the Phase 2 dose escalation study investigating BrainStorm’s NurOwn for the treatment of amyotrophic lateral sclerosis (ALS). NurOwn is a stem cell technology employing adult cells isolated from the disease-affected patient, developed…

Researchers at the National University of Singapore have suggested there is a fine balance between amyotrophic lateral sclerosis (ALS)-related protein TDP-43’s normal function and its potential to cause neurodegeneration. The degeneration seems to occur due to pathological factors that exaggerate the protein’s membrane association, resulting in the loss of its physiological functions as well as…

A research group — coordinated by Giuseppe Legname from The Laboratory of Prion Disease, SISSA, Trieste, Italy — has found a way to build artificial prions, assembling the proteins in a serial manner. The study was performed in collaboration with the Carlo Besta Neurological Institute in Milan and the results were published in the journal…